BRIEF-Shenzhen Chipscreen Biosciences Announces NMPA New Drug Approval Of Bilessglu In China
BRIEF-Shenzhen Chipscreen Biosciences Announces NMPA New Drug Approval Of Bilessglu In China
簡介-深圳芯屏生物科學公司宣佈NMPA新葯在中國獲得Bilessglu批准
Oct 19 (Reuters) - Shenzhen Chipscreen Biosciences Co Ltd
路透10月19日電-深圳晶屏生物科學有限公司
688321.SS :
688321.SS:
* SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD - ANNOUNCES NMPA NEW DRUG APPROVAL OF BILESSGLU (CHIGLITAZAR SODIUM TABLETS) FOR ( TYPE 2 DIABETES) IN CHINA
*深圳CHIPSCREEN生物科學有限公司-宣佈NMPA批准治療2型糖尿病的BILESSGLU(CHIGLITAZAR鈉片)在中國獲得新葯批准
Source text for Eikon: ID:nPn2nXW6va Further company coverage: 688321.SS
Eikon的源文本:ID:nPn2nXW6va進一步的公司報道:688321.SS
((Reuters.Briefs@thomsonreuters.com;))
(Reurs.Briefs@thomsonreurs.com;)